Regenerative Endoscopy for Refractory GI Wall Defects- Endoscopy Feb.26

Introduction

Gastrointestinal wall defects—such as leaks, fistulas, and chronic perforations—remain among the most frustrating complications in GI practice. Even with modern tools (clips, suturing, stents, vacuum therapy), chronic defects with inflamed, fibrotic, retracted margins often refuse to close. Many patients end up in prolonged hospital courses, repeated procedures, or high-risk surgery.

This pilot trial explores a different strategy: rather than forcing closure mechanically, can we biologically “reboot” healing by injecting a regenerative cell-rich product directly into the defect margins?

Problem statement

When a defect becomes chronic, the tissue is no longer “fresh wound biology.” The margins become stiff and fibrotic, blood supply is poor, and standard endoscopic closure often fails even if the edges are approximated.

The unmet need is a therapy that:

• revitalizes scarred tissue,
• supports angiogenesis and mucosal regeneration, and
• can be delivered endoscopically, with low added risk and reasonable cost.

This study evaluates tSVFem (stromal vascular fraction obtained from the patient’s own adipose tissue via mechanical processing) injected endoscopically into the defect border to promote regeneration.

What they did (in plain language)

• Single-center pilot: 30 consecutive patients with difficult defects after conventional options failed or were not possible.
• 15 esophageal defects and 15 rectal defects.
• Under the same session, they harvested a small amount of patient’s hip fat, mechanically processed it (filters + centrifugation), and then injected 1–2 mL into the four quadrants of the defect margins using a standard injection needle.
• For larger defects (≥5 mm), they sometimes used endoscopic suturing to approximate margins, then injected the regenerative product.

Primary endpoint: complete defect closure on endoscopic/radiologic follow-up.

Also tracked: number of sessions, complications, recurrence.

Key results clinicians will care about

1) Esophageal defects responded extremely well

Most esophageal defects closed—often after a single session—and nearly all closed after a second session. Importantly, closure was described as being covered by new vascularized mucosa, suggesting true regenerative healing rather than a fragile seal.

2) Rectal defects improved, but closure was harder

Rectal defects had a more modest overall closure rate, often requiring repeat sessions (sometimes 3–4 treatments). This is clinically intuitive: rectal fistulas/defects are exposed to contamination, pressure dynamics, and complex tract biology.

3) Defects communicating with urinary tract were tougher

Rectal defects involving the urinary system closed less reliably than those communicating with other organs—likely reflecting ongoing inflammation from bacterial colonization, pH differences, and pressure gradients.

4) Safety signal was excellent in this pilot

No intraprocedural or postprocedural adverse events were reported, and there was no recurrence within the short follow-up window.

What this means in practice

This is an early—but highly intriguing—proof-of-concept that regenerative endoscopy is feasible. The technique is attractive because it is:

• Autologous (no rejection risk)
• Minimally manipulated mechanically (important for real-world regulatory feasibility)
• Endoscopically simple (injection needle rather than complex devices)
• Potentially cost-aware compared with repeated advanced closure devices—though repeated sessions can add cost and logistics.

Clinical takeaway

For refractory esophageal defects, tSVFem injection looks particularly promising as a “tissue rescue” strategy.

For rectal defects (especially urinary-tract communication), results are encouraging but incomplete—suggesting the need for:

• protocol refinement,
• better patient/defect selection, and
• possibly combination strategies (e.g., scaffolds, repeated biologic dosing, improved tract control).

Conclusion

Endoscopic injection of autologous, mechanically processed adipose-derived stromal vascular fraction represents a new regenerative tool for complex GI defects—especially in the esophagus—where conventional endoscopic closure is frequently ineffective once fibrosis dominates. Larger controlled studies are now needed to define who benefits most, how many sessions are optimal, and how this approach compares with established endoscopic closure pathways.